Literature DB >> 17803292

Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus.

Hui Xie1, Danny Ng, Sergey N Savinov, Barna Dey, Peter D Kwong, Richard Wyatt, Amos B Smith, Wayne A Hendrickson.   

Abstract

The first step in HIV infection is the binding of the envelope glycoprotein gp120 to the host cell receptor CD4. An interfacial "Phe43 cavity" in gp120, adjacent to residue Phe43 of gp120-bound CD4, has been suggested as a potential target for therapeutic intervention. We designed a CD4 mutant (D1D2F43C) for site-specific coupling of compounds for screening against the cavity. Altogether, 81 cysteine-reactive compounds were designed, synthesized, and tested. Eight derivatives exceeded the affinity of native D1D2 for gp120. Structure-activity relationships (SAR) for derivatized CD4 binding to gp120 revealed significant plasticity of the Phe43 cavity and a narrow entrance. The primary contacts for compound recognition inside the cavity were found to be van der Waals interactions, whereas hydrophilic interactions were detected in the entrance. This first SAR on ligand binding to an interior cavity of gp120 may provide a starting point for structure-based assembly of small molecules targeting gp120-CD4 interaction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17803292      PMCID: PMC2532594          DOI: 10.1021/jm070564e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  50 in total

Review 1.  Antagonists of protein-protein interactions.

Authors:  A G Cochran
Journal:  Chem Biol       Date:  2000-04

2.  Site-directed ligand discovery.

Authors:  D A Erlanson; A C Braisted; D R Raphael; M Randal; R M Stroud; E M Gordon; J A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

3.  Energetics of the HIV gp120-CD4 binding reaction.

Authors:  D G Myszka; R W Sweet; P Hensley; M Brigham-Burke; P D Kwong; W A Hendrickson; R Wyatt; J Sodroski; M L Doyle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

4.  Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.

Authors:  Qian Zhao; Liying Ma; Shibo Jiang; Hong Lu; Shuwen Liu; Yuxian He; Nathan Strick; Nouri Neamati; Asim Kumar Debnath
Journal:  Virology       Date:  2005-09-01       Impact factor: 3.616

5.  Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker.

Authors:  Wen Yuan; Jessica Bazick; Joseph Sodroski
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120.

Authors:  Arne Schön; Navid Madani; Jeffrey C Klein; Amy Hubicki; Danny Ng; Xinzhen Yang; Amos B Smith; Joseph Sodroski; Ernesto Freire
Journal:  Biochemistry       Date:  2006-09-12       Impact factor: 3.162

7.  Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity.

Authors:  Barna Dey; Marie Pancera; Krisha Svehla; Yuuei Shu; Shi-Hua Xiang; Jeffrey Vainshtein; Yuxing Li; Joseph Sodroski; Peter D Kwong; John R Mascola; Richard Wyatt
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

Review 8.  Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor.

Authors:  Kurt Vermeire; Dominique Schols
Journal:  Expert Opin Investig Drugs       Date:  2005-10       Impact factor: 6.206

9.  Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.

Authors:  Hsu-Tso Ho; Li Fan; Beata Nowicka-Sans; Brian McAuliffe; Chang-Ben Li; Gregory Yamanaka; Nannan Zhou; Hua Fang; Ira Dicker; Richard Dalterio; Yi-Fei Gong; Tao Wang; Zhiwei Yin; Yasutsugu Ueda; John Matiskella; John Kadow; Paul Clapham; James Robinson; Richard Colonno; Pin-Fang Lin
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  Structural definition of a conserved neutralization epitope on HIV-1 gp120.

Authors:  Tongqing Zhou; Ling Xu; Barna Dey; Ann J Hessell; Donald Van Ryk; Shi-Hua Xiang; Xinzhen Yang; Mei-Yun Zhang; Michael B Zwick; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Joseph Sodroski; Richard Wyatt; Gary J Nabel; Peter D Kwong
Journal:  Nature       Date:  2007-02-15       Impact factor: 49.962

View more
  18 in total

1.  Synthesis of Kappa Opioid Antagonists Based On Pyrrolo[1,2-α]quinoxalinones Using an N-Arylation/Condensation/Oxidation Reaction Sequence.

Authors:  Sarah M Scarry; Kimberly M Lovell; Kevin J Frankowski; Laura M Bohn; Jeffrey Aubé
Journal:  J Org Chem       Date:  2016-08-02       Impact factor: 4.354

2.  Structure-activity relationship studies of sulfonylpiperazine analogues as novel negative allosteric modulators of human neuronal nicotinic receptors.

Authors:  Brandon J Henderson; Daniel J Carper; Tatiana F González-Cestari; Bitna Yi; Kiran Mahasenan; Ryan E Pavlovicz; Martin L Dalefield; Robert S Coleman; Chenglong Li; Dennis B McKay
Journal:  J Med Chem       Date:  2011-11-18       Impact factor: 7.446

3.  Structure and design of broadly-neutralizing antibodies against HIV.

Authors:  Seong Eon Ryu; Wayne A Hendrickson
Journal:  Mol Cells       Date:  2012-06-25       Impact factor: 5.034

4.  Development of Small Molecules with a Noncanonical Binding Mode to HIV-1 Trans Activation Response (TAR) RNA.

Authors:  Fardokht A Abulwerdi; Matthew D Shortridge; Joanna Sztuba-Solinska; Robert Wilson; Stuart F J Le Grice; Gabriele Varani; John S Schneekloth
Journal:  J Med Chem       Date:  2016-12-02       Impact factor: 7.446

5.  Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120.

Authors:  Rachna Aneja; Adel A Rashad; Huiyuan Li; Ramalingam Venkat Kalyana Sundaram; Caitlin Duffy; Lauren D Bailey; Irwin Chaiken
Journal:  J Med Chem       Date:  2015-04-28       Impact factor: 7.446

6.  Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with HIV-1 surface glycoprotein.

Authors:  Laurence Morellato-Castillo; Priyamvada Acharya; Olivier Combes; Johan Michiels; Anne Descours; Oscar H P Ramos; Yongping Yang; Guido Vanham; Kevin K Ariën; Peter D Kwong; Loïc Martin; Pascal Kessler
Journal:  J Med Chem       Date:  2013-06-11       Impact factor: 7.446

7.  Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 Å cocrystal structure of gp120 and M48U1.

Authors:  Priyamvada Acharya; Timothy S Luongo; Mark K Louder; Krisha McKee; Yongping Yang; Young Do Kwon; John R Mascola; Pascal Kessler; Loïc Martin; Peter D Kwong
Journal:  Structure       Date:  2013-05-23       Impact factor: 5.006

8.  Combinatorial optimization of a CD4-mimetic miniprotein and cocrystal structures with HIV-1 gp120 envelope glycoprotein.

Authors:  François Stricher; Chih-chin Huang; Anne Descours; Sophie Duquesnoy; Olivier Combes; Julie M Decker; Young Do Kwon; Paolo Lusso; George M Shaw; Claudio Vita; Peter D Kwong; Loïc Martin
Journal:  J Mol Biol       Date:  2008-07-01       Impact factor: 5.469

9.  Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-Ray and Thermodynamic Characterization.

Authors:  Judith M Lalonde; Matthew Le-Khac; David M Jones; Joel R Courter; Jongwoo Park; Arne Schön; Amy M Princiotto; Xueling Wu; John R Mascola; Ernesto Freire; Joseph Sodroski; Navid Madani; Wayne A Hendrickson; Amos B Smith
Journal:  ACS Med Chem Lett       Date:  2013-03-14       Impact factor: 4.345

10.  Computational design, synthesis and evaluation of new sulphonamide derivatives targeting HIV-1 gp120.

Authors:  Radhika Vangala; Sree Kanth Sivan; Saikiran Reddy Peddi; Vijjulatha Manga
Journal:  J Comput Aided Mol Des       Date:  2019-12-02       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.